XML 65 R54.htm IDEA: XBRL DOCUMENT v3.26.3
Segment reporting (Schedule of reconciliation to consolidated operating expenses) (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Total research and development expenses $ 1,952,780     $ 1,684,783     $ 9,564,865 $ 5,130,561
Total general and administrative expenses 2,507,476     5,024,082     14,971,257 12,720,666
Total In-Process Research and Development (IPR&D) expenses             0 8,717,475
Total operating expenses 14,460,256     15,426,340     34,536,122 26,568,702
Other income (expense):                
Interest income (expense), net (712,652)     11,572     (1,236,441) 75,442
Loss on SEPA settlements 0     (157,721)     (127,083) (157,721)
Change in fair value of debentures 0     (383,823)     0 (583,823)
Loss on extinguishment of debentures             0 (25,000)
Total other income (expense) (712,652)     (554,972)     (1,363,524) (691,102)
Net loss for the period (15,172,908) $ (11,684,427) $ (9,042,311) (15,981,312) $ (6,176,084) $ (5,102,408) (35,899,646) (27,259,804)
Operating Segments [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Salaries and benefits 2,708,130     519,983     4,235,336 1,395,152
Total research and development expenses 1,952,780     1,684,783     9,564,865 5,130,561
Total general and administrative expenses 2,507,476     5,024,082     14,971,257 12,720,666
Total In-Process Research and Development (IPR&D) expenses 10,000,000     8,717,475     10,000,000 8,717,475
Total operating expenses 14,460,256     15,426,340     34,536,122 26,568,702
Other income (expense):                
Interest income (expense), net (712,652)     11,572     (1,236,441) 75,442
Loss on SEPA settlements 0     (157,721)     (127,083) (157,721)
Change in fair value of debentures 0     (383,823)     0 (583,823)
Loss on extinguishment of debentures 0     (25,000)     0 (25,000)
Total other income (expense) (712,652)     (554,972)     (1,363,524) (691,102)
Net loss for the period (15,172,908)     (15,981,312)     (35,899,646) (27,259,804)
Operating Segments [Member] | SkinJect [Member] | Clinical, manufacturing and regulatory activities [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research and development expenses 464,223     1,114,470     2,475,511 3,568,401
Operating Segments [Member] | SkinJect [Member] | Professional services and intellectual property [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research and development expenses 51,558     49,092     196,785 165,770
Operating Segments [Member] | Teverelix [Member] | Clinical, manufacturing and regulatory activities [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research and development expenses (1,389,137)     1,238     2,460,885 1,238
Operating Segments [Member] | Teverelix [Member] | Professional services and intellectual property [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research and development expenses 37,358     0     115,699 0
Operating Segments [Member] | CD228V [Member] | Professional services and intellectual property [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Research and development expenses $ 80,649     $ 0     $ 80,649 $ 0